PortfoliosLab logoPortfoliosLab logo
CVKD vs. AYTU
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

CVKD vs. AYTU - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Cadrenal Therapeutics Inc. Common Stock (CVKD) and Aytu BioPharma, Inc. (AYTU). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

CVKD vs. AYTU - Yearly Performance Comparison


2026 (YTD)202520242023
CVKD
Cadrenal Therapeutics Inc. Common Stock
-24.48%-53.21%30.56%-82.04%
AYTU
Aytu BioPharma, Inc.
1.54%52.94%-40.14%-19.77%

Fundamentals

Market Cap

CVKD:

$10.21M

AYTU:

$26.50M

EPS

CVKD:

-$5.10

AYTU:

-$2.02

PB Ratio

CVKD:

3.73

AYTU:

1.87

Total Revenue (TTM)

CVKD:

$0.00

AYTU:

$62.64M

Gross Profit (TTM)

CVKD:

-$5.92K

AYTU:

$41.34M

EBITDA (TTM)

CVKD:

-$13.32M

AYTU:

-$17.24M

Returns By Period

In the year-to-date period, CVKD achieves a -24.48% return, which is significantly lower than AYTU's 1.54% return.


CVKD

1D
20.47%
1M
-39.69%
YTD
-24.48%
6M
-62.98%
1Y
-70.96%
3Y*
-37.68%
5Y*
10Y*

AYTU

1D
-3.30%
1M
-0.00%
YTD
1.54%
6M
41.18%
1Y
127.59%
3Y*
5.63%
5Y*
-55.49%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

CVKD vs. AYTU — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CVKD
CVKD Risk / Return Rank: 77
Overall Rank
CVKD Sharpe Ratio Rank: 1010
Sharpe Ratio Rank
CVKD Sortino Ratio Rank: 99
Sortino Ratio Rank
CVKD Omega Ratio Rank: 1010
Omega Ratio Rank
CVKD Calmar Ratio Rank: 55
Calmar Ratio Rank
CVKD Martin Ratio Rank: 33
Martin Ratio Rank

AYTU
AYTU Risk / Return Rank: 8585
Overall Rank
AYTU Sharpe Ratio Rank: 7575
Sharpe Ratio Rank
AYTU Sortino Ratio Rank: 9191
Sortino Ratio Rank
AYTU Omega Ratio Rank: 8989
Omega Ratio Rank
AYTU Calmar Ratio Rank: 8484
Calmar Ratio Rank
AYTU Martin Ratio Rank: 8484
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CVKD vs. AYTU - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Cadrenal Therapeutics Inc. Common Stock (CVKD) and Aytu BioPharma, Inc. (AYTU). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


CVKDAYTUDifference

Sharpe ratio

Return per unit of total volatility

-0.74

1.09

-1.83

Sortino ratio

Return per unit of downside risk

-1.18

3.01

-4.19

Omega ratio

Gain probability vs. loss probability

0.86

1.39

-0.53

Calmar ratio

Return relative to maximum drawdown

-0.95

2.83

-3.78

Martin ratio

Return relative to average drawdown

-1.81

7.53

-9.35

CVKD vs. AYTU - Sharpe Ratio Comparison

The current CVKD Sharpe Ratio is -0.74, which is lower than the AYTU Sharpe Ratio of 1.09. The chart below compares the historical Sharpe Ratios of CVKD and AYTU, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading graphics...

Sharpe Ratios by Period


CVKDAYTUDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.74

1.09

-1.83

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.65

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.53

-0.36

-0.18

Correlation

The correlation between CVKD and AYTU is 0.11, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Dividends

CVKD vs. AYTU - Dividend Comparison

Neither CVKD nor AYTU has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

CVKD vs. AYTU - Drawdown Comparison

The maximum CVKD drawdown since its inception was -93.12%, smaller than the maximum AYTU drawdown of -100.00%. Use the drawdown chart below to compare losses from any high point for CVKD and AYTU.


Loading graphics...

Drawdown Indicators


CVKDAYTUDifference

Max Drawdown

Largest peak-to-trough decline

-93.12%

-100.00%

+6.88%

Max Drawdown (1Y)

Largest decline over 1 year

-75.95%

-42.47%

-33.48%

Max Drawdown (5Y)

Largest decline over 5 years

-99.34%

Current Drawdown

Current decline from peak

-91.72%

-100.00%

+8.28%

Average Drawdown

Average peak-to-trough decline

-78.08%

-95.05%

+16.97%

Ulcer Index

Depth and duration of drawdowns from previous peaks

39.89%

15.93%

+23.96%

Volatility

CVKD vs. AYTU - Volatility Comparison

Cadrenal Therapeutics Inc. Common Stock (CVKD) has a higher volatility of 30.09% compared to Aytu BioPharma, Inc. (AYTU) at 10.33%. This indicates that CVKD's price experiences larger fluctuations and is considered to be riskier than AYTU based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading graphics...

Volatility by Period


CVKDAYTUDifference

Volatility (1M)

Calculated over the trailing 1-month period

30.09%

10.33%

+19.76%

Volatility (6M)

Calculated over the trailing 6-month period

78.40%

38.47%

+39.93%

Volatility (1Y)

Calculated over the trailing 1-year period

95.64%

117.92%

-22.28%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

101.78%

85.84%

+15.94%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

101.78%

190.00%

-88.22%

Financials

CVKD vs. AYTU - Financials Comparison

This section allows you to compare key financial metrics between Cadrenal Therapeutics Inc. Common Stock and Aytu BioPharma, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.005.00M10.00M15.00M20.00M25.00M30.00M35.00MJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober0
15.17M
(CVKD) Total Revenue
(AYTU) Total Revenue
Values in USD except per share items